Sanofi ADR (SNY) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$1.14	$1.2	+5.3%	—	$12.3B	—
Q1 26	$1.03	$1.1	+6.8%	—	$11.2B	—
Q4 25	$0.85	$0.91	+7.1%	—	$12.2B	—
Q3 25	$1.57	$1.69	+7.6%	—	$13.2B	—
Q2 25	$1	$0.91	-9.0%	—	—	—
Q1 25	$0.95	$1.02	+7.4%	—	—	—
Q4 24	$0.74	$0.68	-8.1%	—	—	—
Q3 24	$1.38	$1.54	+11.6%	—	—	—
Q2 24	$0.86	$0.93	+8.1%	—	—	—
Q1 24	$0.94	$0.95	+1.1%	—	—	—
Q4 23	$0.91	$0.9	-1.1%	—	—	—
Q3 23	$1.37	$1.35	-1.5%	—	—	—
Q2 23	$0.89	$0.96	+7.9%	—	$10.7B	—
Q1 23	$1.1	$1.19	+8.2%	—	$10.9B	—
Q4 22	$0.91	$0.93	+2.2%	—	$11.5B	—
Q3 22	$1.34	$1.44	+7.5%	—	$13.1B	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$3.2	—	—	$46.7B	—
FY24	—	$2.29	—	—	$53B	—
FY23	—	$2.15	—	—	$46.4B	—
FY22	—	$3.35	—	—	$45.4B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$34.7B	$36.2B	$35.7B	$37.6B	$37.4B	$39.2B	$45.4B	$46.4B	$53B	$46.7B
YoY change	-0.47%	+4.4%	-1.5%	+5.48%	-0.7%	+4.83%	+15.9%	+2.32%	+14.1%	-11.8%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	34.7B	36.2B	35.7B	37.6B	37.4B	39.2B	45.4B	46.4B	53B	46.7B
Cost of revenue	10.7B	11.6B	11.4B	12B	12.2B	12.3B	13.7B	14.2B	15.8B	13B
Gross profit	24B	24.6B	24.2B	25.7B	25.2B	26.9B	31.7B	32.2B	37.2B	33.7B
Gross margin	69.2%	67.9%	67.9%	68.2%	67.5%	68.7%	69.8%	69.3%	70.2%	72.1%
Research & development	5.2B	5.5B	5.9B	6B	5.5B	5.7B	6.7B	6.7B	8.8B	7.8B
Selling, general & administrative	9.5B	10.1B	9.9B	9.9B	9.4B	9.6B	10.5B	10.7B	11B	10.2B
Operating expenses	14.8B	15.5B	15.8B	16.3B	15.6B	16.2B	17.8B	19.6B	23.8B	22.3B
Operating income	7.5B	7.2B	6.3B	7.2B	7.9B	9.1B	11.9B	10.4B	11.3B	9.6B
Operating margin	21.7%	19.9%	17.5%	19.1%	21.1%	23.3%	26.2%	22.4%	21.4%	20.5%
Non-operating income, net	-995M	-1.4B	-1.5B	-4.1B	6.2B	-979M	-1.2B	-2.6B	-2.6B	-3.3B
Pretax income	5.7B	5.5B	4.4B	2.8B	13.8B	7.8B	10.4B	7.2B	8B	6.2B
Income tax	1.3B	1.7B	481M	121M	1.8B	1.6B	2B	1.6B	1.4B	1B
Net income	4.8B	8.5B	4.4B	2.8B	12.3B	6.3B	8.5B	5.4B	6.7B	7.9B
Net margin	13.8%	23.6%	12.4%	7.4%	33%	16%	18.7%	11.7%	12.7%	16.8%
EBITDA	11.1B	10.8B	11.2B	15.1B	11.8B	12.5B	15.5B	15.2B	15.8B	15.8B
EPS	1.83	3.35	1.73	1.1	4.91	2.48	3.35	2.15	2.29	3.2
Diluted EPS	1.81	3.32	1.72	1.09	4.88	2.48	3.33	2.15	2.29	3.2

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	—	—	—	—	—	—	—	—	13.2B	12.2B	11.2B	12.3B
Cost of revenue	—	—	—	—	—	—	—	—	3.4B	3.8B	3.1B	3B
Gross profit	—	—	—	—	—	—	—	—	9.8B	8.4B	8.1B	9.3B
Gross margin	—	—	—	—	—	—	—	—	74.1%	69.2%	72.1%	75.5%
Research & development	—	—	—	—	—	—	—	—	1.8B	2.3B	1.7B	2.2B
Selling, general & administrative	—	—	—	—	—	—	—	—	2.3B	3.4B	2.5B	2.6B
Operating expenses	—	—	—	—	—	—	—	—	5.5B	6.3B	5.3B	6.3B
Operating income	—	—	—	—	—	—	—	—	3.8B	1.6B	2.3B	2.4B
Operating margin	—	—	—	—	—	—	—	—	28.7%	13.4%	20.2%	19.4%
Non-operating income, net	—	—	—	—	—	—	—	—	-161M	-2.7B	-148M	-1.3B
Pretax income	3B	-121M	1.1B	1.6B	4.1B	456M	2.2B	1.4B	3.5B	-917M	2B	837M
Income tax	—	—	—	—	—	—	—	—	680M	-348M	420M	451M
Net income	—	—	—	—	—	—	—	—	2.8B	-794M	1.6B	377M
Net margin	—	—	—	—	—	—	—	—	21.3%	-6.51%	14.4%	3.07%
EBITDA	—	—	—	—	—	—	—	—	4.4B	2.4B	2.9B	3B
EPS	1	-0.22	0.46	—	1.13	0.27	0.76	—	1.15	-0.33	0.67	0.14
Diluted EPS	1	-0.22	0.46	—	1.13	0.27	0.76	—	1.15	-0.33	0.67	0.14

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	100.4B	104.3B	104.5B	121.1B	117.6B	121.1B	117B	118.7B	—	—	98.7B
Enterprise value	108.7B	109.5B	122B	137.2B	128.8B	132.4B	124.8B	128.1B	—	—	132.2B
Shares outstanding	2.5B	2.4B	2.4B	2.4B	2.4B	2.4B	2.4B	2.4B	3B	2.4B	2.4B

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	20.9	12.2	23.7	43.5	9.53	19.3	13.8	21.8	—	—	22.3
P/S	2.89	2.88	2.93	3.22	3.15	3.09	2.58	2.55	—	—	2.01
P/B	1.74	1.79	1.77	2.04	1.7	1.75	1.56	1.6	—	—	1.22
EV/EBITDA	9.79	10.1	10.9	9.08	10.9	10.6	8.07	8.43	—	—	8.57
EV/Sales	3.13	3.02	3.42	3.65	3.45	3.38	2.75	2.76	—	—	2.37
Earnings yield	4.78%	8.18%	4.22%	2.3%	10.5%	5.18%	7.25%	4.58%	—	—	4.48%
FCF yield	6.08%	5.2%	3.42%	4.9%	4.54%	7%	7.11%	6.1%	—	—	7.27%
PEG	—	—	—	—	—	—	—	—	—	—	7.6

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	69.2%	67.9%	67.9%	68.2%	67.5%	68.7%	69.8%	69.3%	70.2%	72.1%	75.5%
Operating margin	21.7%	19.9%	17.5%	19.1%	21.1%	23.3%	26.2%	22.4%	21.4%	20.5%	21%
Net margin	13.8%	23.6%	12.4%	7.4%	33%	16%	18.7%	11.7%	12.7%	16.8%	8.09%
ROE	8.32%	14.7%	7.47%	4.7%	17.9%	9.1%	11.3%	7.31%	7.22%	10.9%	5.71%
ROA	4.59%	8.55%	3.96%	2.47%	10.3%	5.22%	6.69%	4.3%	4.23%	6.19%	5.09%
ROIC	8.74%	7.82%	7.28%	9.11%	8.54%	9.12%	11.6%	9.62%	8.84%	9.54%	9.03%
Return on tangible assets	204.5%	-124.2%	-21.2%	-29.5%	-66%	-33.6%	-51.9%	-25.9%	727.7%	-94.4%	-53%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	1.88	1.71	1.42	1.42	1.44	1.44	1.42	1.27	1.46	1.09	0.99
Quick ratio	1.49	1.27	0.99	1.03	1.03	1.03	1.05	0.87	1.14	0.73	0.64
Debt / equity	0.32	0.27	0.42	0.44	0.32	0.32	0.28	0.25	0.23	0.28	0.34
Debt / assets	0.18	0.16	0.22	0.23	0.19	0.19	0.17	0.15	0.13	0.16	0.18
Net debt / EBITDA	0.75	0.48	1.57	1.06	0.95	0.9	0.5	0.62	0.75	0.75	1.37
Interest coverage	7.14	14.2	9.9	6.92	32.7	21	23.6	11.9	9.94	10.9	8.44
Effective tax rate	23.3%	31.1%	10.9%	4.4%	13.1%	20%	19.2%	22.4%	18%	16.9%	22.1%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	14	14.9	14.8	15.6	15.4	16.2	18.8	19.5	17.7	19.1	20.3
EPS (basic)	1.83	3.35	1.73	1.1	4.91	2.48	3.35	2.15	2.29	3.2	3.2
EPS (diluted)	1.81	3.32	1.72	1.09	4.88	2.48	3.33	2.15	2.29	3.2	1.84
Book value per share	23.2	24	24.5	24.6	28.5	28.6	31.1	31.2	31.1	29.4	33.6
FCF per share	2.46	2.24	1.48	2.46	2.21	3.51	3.45	3.03	2.35	2.95	3.52
Cash per share	4.15	4.28	2.96	4.08	4.61	4.61	5.55	3.76	3.17	3.47	2.65
Capex per share	0.75	0.59	0.08	0.23	0.48	0.57	0.3	0.84	0.69	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	5.4%	3.92%	0.52%	1.5%	3.12%	3.49%	1.57%	4.33%	3.92%	—	—
Capex / operating cash flow	23.7%	20.5%	2.74%	7.19%	7.87%	12.9%	6.63%	19.5%	22.2%	—	—
Payout ratio	78.3%	43.5%	85.6%	137.7%	31.9%	63.8%	49.1%	81.9%	83.7%	60.8%	128.2%
Dividend yield	3.74%	3.56%	3.61%	3.17%	3.35%	3.31%	3.56%	3.75%	—	—	23.5%

Yield

23.5%

trailing twelve months

Frequency

Annual

Last dividend

$2.4225

ex-dividend May 4, 2026

Payout ratio

128%

of earnings

Dividend growth

2 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
May 4, 2026	$2.4225
May 9, 2025	$2.2122
May 9, 2024	$2.0369
May 30, 2023	$1.9001
May 26, 2022	$0.2972
May 4, 2022	$1.7968
May 3, 2021	$1.9061
Apr 30, 2020	$1.6994

Split history

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	—	—	—	—	—	—	—	—	$13.2B	$12.2B	$11.2B	$12.3B
YoY change	—	—	—	—	—	—	—	—	—	—	—	—

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	10.3B	10.4B	7.1B	9.9B	11.2B	11.2B	13.4B	9B	9.5B	8.5B
Receivables	7.3B	7.2B	7.3B	7.9B	7.6B	7.6B	8.4B	8.4B	9.2B	8.4B
Inventory	6.9B	6.8B	7.5B	8B	8.7B	8.7B	9B	9.7B	11.3B	10.2B
Total current assets	33.1B	26.4B	24.6B	28.9B	30.7B	30.7B	34.1B	30.7B	51B	31B
Property, plant & equipment	3.1B	2.8B	2.8B	3.7B	4.8B	4.8B	4.4B	4.1B	5B	4.4B
Goodwill & intangibles	102.3B	106.7B	132.2B	122.1B	138.9B	138.9B	143.1B	147.4B	158B	135.1B
Total assets	104.7B	99.8B	111.4B	112.6B	120.2B	120.2B	126.7B	126.5B	158.9B	126.8B
Accounts payable	4.3B	4.6B	5B	5.3B	6.2B	6.2B	6.8B	7.3B	9B	7.4B
Short-term debt	1.8B	1.3B	2.6B	4.8B	3.5B	3.5B	4.5B	2.3B	5.3B	4.6B
Total current liabilities	17.6B	15.5B	17.4B	20.4B	21.3B	21.3B	24B	24.2B	34.9B	28.3B
Long-term debt	16.8B	14.3B	22B	21.1B	19B	19B	16.8B	16.1B	16.1B	15.7B
Total liabilities	47B	41.6B	52.4B	53.4B	51.2B	51.2B	51.6B	52.1B	65.7B	55.1B
Shareholders' equity	57.7B	58.2B	59B	59.2B	69B	69B	75.2B	74.4B	93.2B	71.7B
Total debt	18.6B	15.6B	24.6B	25.9B	22.4B	22.4B	21.2B	18.4B	21.4B	20.3B
Net debt	8.3B	5.3B	17.7B	16.5B	12.3B	12.3B	8.5B	9.7B	12.5B	12.7B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q2 22	Q4 22	Q2 23	Q4 23	Q2 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	6.9B	13.4B	8B	—	—	—	—	—	8.9B	8.5B	5.5B	6.3B
Receivables	7.9B	8.4B	8.3B	—	—	—	—	—	—	8.4B	—	8.7B
Inventory	9.4B	9B	10B	—	—	—	—	—	24.5B	10.2B	23.5B	11.1B
Total current assets	28.6B	34.1B	30.2B	—	—	—	—	—	34B	31B	30.2B	31.5B
Property, plant & equipment	11.6B	4.4B	11.5B	—	—	—	—	—	11.2B	4.4B	11.7B	12B
Goodwill & intangibles	145.1B	143.1B	147.7B	—	—	—	—	—	68.9B	135.1B	69.1B	136.6B
Total assets	121.8B	126.7B	125.4B	—	—	—	—	—	129.8B	126.8B	128B	129.1B
Accounts payable	6.6B	6.8B	7.4B	—	—	—	—	—	22B	7.4B	22.7B	7.2B
Short-term debt	3.3B	4.5B	4.9B	—	—	—	—	—	8.5B	4.6B	6.2B	7.3B
Total current liabilities	22.1B	24B	24.8B	—	—	—	—	—	32.1B	28.3B	30B	31.9B
Long-term debt	17.9B	16.8B	16.1B	16.1B	16.5B	13.4B	13.4B	14.7B	13.3B	15.7B	13.8B	16.3B
Total liabilities	50.5B	51.6B	52.4B	—	—	—	—	—	56.3B	55.1B	54.9B	59.5B
Shareholders' equity	71.3B	75.2B	72.9B	—	—	—	—	—	73.5B	71.7B	73.1B	69.6B
Total debt	21.2B	21.2B	21B	16.1B	16.5B	13.4B	13.4B	14.7B	21.8B	20.3B	20B	23.6B
Net debt	14.3B	8.5B	13B	—	—	—	—	—	12.8B	12.7B	14.5B	17.2B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	4.7B	8.4B	4.3B	2.8B	12.3B	6.2B	8.4B	5.4B	6.6B	4.9B
Depreciation & amortization	3.3B	3.7B	4.3B	7.4B	3.7B	3.4B	3.4B	4.8B	4.3B	5.7B
Stock-based compensation	—	—	—	—	—	—	—	—	—	—
Change in working capital	830M	147M	-1.3B	-419M	-325M	1.4B	-707M	764M	-735.9M	1.8B
Operating cash flow	7.9B	6.9B	6.8B	7.8B	14.8B	10.6B	10.8B	10.3B	9.3B	10.8B
Capital expenditure	-1.9B	-1.4B	186M	-563M	-1.2B	-1.4B	-713M	-2B	-2.1B	—
Investing cash flow	-2.5B	-2.9B	-12.9B	-1.2B	3.6B	-7.3B	-2.1B	-6.2B	-5.1B	-10.2B
Dividends paid	-3.8B	-3.7B	-3.8B	-3.8B	-3.9B	-4B	-4.2B	-4.5B	-5.6B	-4.8B
Share repurchases	-2.9B	-2.2B	-1.1B	-9M	-822M	-382M	-497M	-593M	-361.4M	-5B
Financing cash flow	-4.1B	-7.9B	3.9B	-4.2B	-6.5B	-7.1B	-5.8B	-8.1B	-6.9B	-8.2B
Net change in cash	1.3B	-3.9B	-2.1B	2.5B	11.9B	-3.7B	2.9B	-3.9B	-2.7B	-7.6B
Free cash flow	6.1B	5.4B	3.6B	5.9B	5.3B	8.5B	8.3B	7.2B	7B	7.2B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q2 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	—	—	—	—	—	—	—
Depreciation & amortization	—	—	—	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	—
Change in working capital	—	—	—	—	—	—	—
Operating cash flow	—	—	1.5B	3.8B	3.4B	1.7B	3B
Capital expenditure	—	—	—	—	—	—	—
Investing cash flow	322M	-767M	735M	-10.9B	10.9B	-2.1B	2.1B
Dividends paid	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—
Financing cash flow	-791M	-584M	557M	-5.6B	5.6B	-1.5B	1.5B
Net change in cash	-469M	-1.4B	2.8B	-12.7B	19.9B	-1.9B	6.5B
Free cash flow	-551M	2.1B	42M	5.2B	-93M	1.7B	1.7B

Sep 30, 2013	5:1
Nov 17, 2010	10:1

Sanofi ADR Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Split history

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement